Article PDF
Avoid common mistakes on your manuscript.
References
Australian drug evaluation committee (1988) Guidelines for the production of monoclonals intended for therapeutic use, National Biological Standards Laboratory, Common-wealth Department of Health.
Bartal AH, Feit C, Erlandson R and Hirshaut Y (1982) The presence of virus particles in clones secreting monoclonal antibodies. New Med. 306(23): 1423.
Bartal AH and Hirshaut Y (1987) Retrovirus and hybridoma formation, bystanders or active participants? In: Bartal and Hirshaut (eds) Methods of Hybridoma formation (pp. 41–61) Humana Press, USA.
Builder SE, Ogez JR, Van Reis R, Paoni NF, Arathoon R and Lubiniecki AS (1989) Process development and regulatory control of tissue type plasminogen activator. In: Spier RE, Griffiths JB, Crooy P and Stephenne J (eds) Advances in animal cell biology and technology (pp. 452–464) Butterworths, Guildford.
Carthew P (1986) Is rodent virus contamination of monoclonal antibody preparations for use in human therapy a hazard? J. Gen. Virol. 67: 963–974.
Cloyd MW, Hartley JW and Rowe WP (1981) Genetic study of lymphoma induction by AKR mink cell focus-inducing virus in AKRxNFS crosses. J. Exp. Med. 154: 450–459.
Collet MC, Moennig V and Hurtinek MC (1989) Recent advances in pestivirus research. J. Gen. Virol. 70: 253–266.
Collins MJ and Parker JC (1972) Murine viral contaminants of leukemia viruses and transplantable tumours. J. Nat. Cancer Inst. 49: 1139–1143.
Commission of the European Communities (1988) Guidelines on the production and quality control of monoclonal antibodies of murine origin intended for use in man. TIB-TECH 6: G5-G8.
Crawford DH, Huehns ER and Epstein MA (1983) Therapeutic use of antibodies. Lancet i: 1040.
Crawford DH and Azim T (1987) The use of the Epsteinbarr virus for the production of human monoclonal antibody secreting cell lines. In: Brown J (ed) Human monoclonal antibodies (pp. 1–6). IRL Press, Oxford, Washington DC.
Doel JR (1985) Inactivation of viruses produced in animal cell culture. In: Spier RE and Griffiths JB (eds) Animal cell biotechnology (pp. 129–149). Academic Press, London.
Finter MB and Fantes KH (1980) The purity and safety of interferons prepared for clinical use (: the case for lymphoblastoid interferons) In: Gresser (ed) Interferon 2 1980 (pp. 65–80). Academic Press, New York.
Griffiths JB (1988) Cell substrates and world health. Cytotechnology 1: 111–112.
Harnomoto Y, Kobayashe S, Yamaguchi K, Iikima H, Manabe S, Tsurumi T, Aizawa H and Yamamoto N (1989) A novel filtration method for removal of human immunodeficiency virus: filtration with porous polymeric membranes. Vox Sang. 56: 230–236.
Harbour C, MacLeod AL, Reid KG and McIntosh RV (1989) Viral inactivation strategies for monoclonal antibodies: dry heating. Biotech. Techniques 3: 261–264.
Heine UI, Kramarsky B, Wendel E and Suskind RG (1979) Enhanced proliferation of endogenous virus in Chinese hamster cells associated with microtubules and the mitotic apparatus of the host cell. J. Gen. Virol. 44: 45–55.
Heinrich D, Sugg U, Brackman HH, Stephan W and Lissener R (1987) Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences. Develop. Biol. Standard. 67: 311–317.
Heldebrant CM, Gomperts ED, Kasper CK, McDougal JS, Friedman AE, Hwang DS, Mushmore E, Jordan S, Miller R, Sergis-D E and Lam W (1985) Evaluation of two viral inactivation methods for the preparation of safer Factor VIII and Factor IX concentrates. Transfusion 25: 510–515.
Horowitz B, Piet MPJ, Prince AM, Edwards CA, Lippin A and Walakouits L (1988) Inactivation of lipid enveloped viruses in labile blood derivatives by unsaturated fatty acids. Vox Sang. 54: 14–20.
Horowitz B, Wiebe ME, Lippin A, Vandersa J and Stryker MH (1985) Inactivation of viruses in labile blood derivatives. Transfusion 25: 523–527.
Jiang Shu de, Bye D and Cox JC (1986) Inactivation of poliovirus with beta-propiolactone. J. Biol. Standard. 14: 103–109.
Jungi TW, Santer M, Lerch P and Barandun S (1986) Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte receptors. Vox Sang. 51: 18–26.
Kacian DL, and Spiegelman S (1974) Purification and detection of reverse transcriptase in viruses and cells. Meth. Enzymol. 29E: 150–173.
Klement W, Rowe WP, Hartley JW and Pugh WE (1969) Mixed culture cytopathogenicity: a new test for growth of murine leukemia viruses in tissue culture. Proc. Nat. Acad. Sci. 63: 753–758.
Kuwert W, Rowe WP, Hartley JW and Pugh WE (1977) Post-exposure use of human diploid cell culture rabies vaccine. Devel. Biol. Standard 37: 123–127.
Lever AML, Webster ADB, Brown D and Thomas HC (1984) Non-A, non-B hepatitis occurring in gammaglobulamic patients after intravenous immunoglobulin. Lancet II: 1062–1064.
Levy JA (1983) Mouse plasmacytoma cells produce infectious type C particles. Lancet II: 522.
Levy JA, Lee HM, Kawahata RT, and Spitler LE (1984) Purification of monoclonal antibodies from mouse ascites eliminates contaminating infectious mouse type C viruses and nucleic acids. Clin. Exp. Immunol. 56(1): 114–120.
Levy JA, Mitra GA, Wong MF and Mozen MM (1985) Inactivation by wet and dry heat of AIDS associated retroviruses during factor VIII purification from plasma. Lancet I: 1456–1457.
Liu WT, Natori T, Chang KS and Wu AM (1977) Reverse transcriptase of foaming virus. Purification of the enzymes and immunological identification. Arch. Virol. 55(3): 187–200.
LeGrippo GA (1960) Investigation of the use of betapropiolactone in virus inactivation. Ann. N.Y. Acad. Sci. 83: 578–594.
LeGrippo GA and Hartman FW (1955) Antigenicity of beta-propiolactone inactivated by virus vacines. J. Immunol. 75: 123–127.
LoGrippo GA, Wolfram BR and Rupe C (1964) Human plasma treated with ultraviolet and propiolactone, a six year clinical evaluation. J.A.M.A. 178: 722–726.
Lubiniecki AS (1989) Endogenous retrovirus of continuous cell substrates. In: Spier RE, Griffiths JB, Crooy P and Stephenne J (eds) Advances in animal cell biology and technology for bioprocesses (pp. 85–92). Butterworths, Guildford.
Lubiniecki AS and May LH (1985) Cell bank characterization for recombinant DNA mammalian cell lines. Develop. Biol. Standard. 60: 141–146.
Lusher JM, Lamon KD and the monoclate study group (1988) A multicentre study to determine the hepatitis safety of monoclate, a new highly purified FVIII:C preparation. XVIII international congress of the world federation of haemophilia: Madrid, May 26–31, 1988: abstr p. 124.
MacLeod AJ (1988) The use of plasma protein fractions as medium supplements for animal cell culture. In: A Flechter (ed) Advances in biochemical engineering and biotechnology (37: 41–56) Springer Verlag.
Manley KF, Givens JF, Taber RL and Ziegel FF (1978) Characterization of virus like particles released from the hamster cell line CHO-K1 after treatment with 5-bromodeoxyuridine. J. Gen. Virol. 39(3): 505–517.
Mannucci PM, and Colombo M (1988) Virucidal treatment of clotting factor concentrates. Lancet II: 782–785.
Martin DW (1985) An overview of risk association with viruses endogenous to cell substrates. In: Hopps HE and Petriccani JC (eds) Abnormal cells, new products and risks (pp. 29–35). Tissue culture association, Gaithersburg.
Moyer MP and Moyer RC (1987) Potential risks of tumour viruses subgenomes in the production of biologicals. Develop. Biol. Standard. 68: 51–62.
Nelson JM (1988) Intravenous immunoglobulin: silver bullet of the 80s. Lab. Medicine 19: 799–805.
Ochs HD (1985) Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet I: 404.
Onions DE, Lees GM and Sear CHJ (1989) Retroviruses: new problems and new solutions in the safety testing of biologicals for regulatory approval. In: Spier RE, Griffiths JB, Crooy P and Stephenne J (eds) Advances in animal cell biology and technology for bioprocesses (pp. 72–75). Butterworths, Guidford.
Peebles PT (1975) An in vitro induction assay for xenotropic murine leukaemia viruses, feline leukaemia virus C, and the feline primate viruses RD-114/CC/M-7. Virology 67: 288–296.
Petricciani JC, McDougal JS and Evatt BL (1985) Case for concluding that heat-treated licensed anti-haemophilic factor is free from HTLV-III. Lancet II: 890–891.
Petricciani JC and Regan PJ (1987) Risk of neoplastic transformation from cellular DNA: calculation using the oncogene model. Develop. Biol. Standard. 68: 43–49.
Petricciani JC, Salk PL, Salk J and Noguchi PD (1981) Theoretical considerations and practical concerns regarding the use of continuous cell lines in the production of biologics. Develop. Biol. Standard. 50: 15–25.
Prince AM, Stephan W and Brotman B (1983) Betapropiolactone ultraviolet irradiation: a review of its effectiveness for inactivation of viruses in blood derivatives. Rev. Infect. Dis. 5: 92–107.
Prince AM, Horowitz B and Brotman B (1986) Sterilization of hepatitis and HTLV-III viruses by exposure to tri(-n-butyl)phosphate and sodium cholate. Lancet I: 706–710.
Prince AM, Horowitz B, Brotman B, Huima T, Richards L and Van derEnde M (1984) Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to tween 80 and ether. Vox Sang. 46: 36–43.
Quinnan GV, Wells MA, Wittek AE, Phelan MA. Mayner RE, Feinston S, Purcell RH and Epstein JS (1985) Inactivation of human T-cell lymphotropic virus, type III by heat, chemicals and irradiation. Transfusion 26: 485–483.
Reid KG, Cuthbertson B, Jones ADL and McIntosh RV (1988) The potential contribution of mild pepsin treatment at pH 4 to the viral safety of human immunoglobulin products. Vox Sang. 55: 75–80.
Shek WR (1987) Detection of murine viruses in biological materials by the mouse antibody production test. In: Seaver SS (ed) Commercial production of antibodies (pp. 3–16). Marcel Dekker, Inc. NY & Basel.
Smith JK, Winkleman L, Evans DR, Haddon ME and Sims G (1985) A pasteurized antithrombin III concentrate for clinical use. Vox Sang. 48: 325–332.
Stephan W and Kotitschk (1987) Safety of beta-propiolactone/UV treated PPSB (factor IX concentrate). Thromb. Res. Suppl. VII: 58.
Weiss RA (1982a) Retroviruses produced by hybridomas. New Eng. J. Med. 307: 1587.
Weiss RA (1982b) Hybridomas produce viruses as well as antibodies. Immunol. Today 3: 292–294.
Welch AG, McIntosh RV and Foster PR (1983) Non-A, non-B hepatitis from intravenous immunoglobulin. Lancet II: 1198–1199.
WHO Technical report series (1987) No. 747.
Wiebe ME, Beker F, Lazar R, May L, Casto B, Semense M, Fautz C, Garnick R, Miller C, Masover G, Bergmann D and Lubiniecki AS (1989) A multifaceted approach to assure that recombinant tPA is free of adventitious virus. In: Spier RE, Griffiths JB, Crooy P and Stephenne J (eds) Advances in animal cell biology and technology for bioprocesses (pp. 68–71). Butterworths, Guildford.
Winkleman L, Owen NE, Haddon ME and Smith JK (1985) Treatment of a new high specific activity factor VIII concentrate to inactivate viruses. Thromb. haemostas. 54: 19.
Wurm FM, Williams SR, Anderson K, Dinowitz M, Obijeski J and Arathoon R (1989) Presence and transcription of endogenous retroviral sequences in chinese hamster ovary cells. In: Spier RE, Griffiths JB, Crooy P and Stephenne J (eds) Advances in animal cell biology and technology for bioprocesses (pp. 76–81). Butterworths, Guildford.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harbour, C., Woodhouse, G. Viral contamination of monoclonal antibody preparations: Potential problems and possible solutions. Cytotechnology 4, 3–12 (1990). https://doi.org/10.1007/BF00148806
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00148806